AP NEWS

Fibromyalgia Pipeline Review, H2 2018 - Therapeutic Assessment of 12 Companies - ResearchAndMarkets.com

September 25, 2018

DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The ” Fibromyalgia - Pipeline Review, H2 2018 ” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Fibromyalgia - Pipeline Review, H2 2018 provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 2, 7, 1, 2, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Report Coverage Fibromyalgia - Overview Fibromyalgia - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Fibromyalgia - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Companies Involved in Therapeutics Development Abide Therapeutics Inc Aptinyx Inc Astellas Pharma Inc Daiichi Sankyo Co Ltd Innovative Med Concepts LLC Intec Pharma Ltd Jiangsu Hengrui Medicine Co Ltd Luye Pharma Group Ltd Merck & Co Inc Pfizer Inc Prismic Pharmaceuticals Inc Vitality Biopharma Inc For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vl5gtd/fibromyalgia?w=4.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925006183/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Musculoskeletal Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: EDUCATION UNIVERSITY HEALTH CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/25/2018 04:47 PM/DISC: 09/25/2018 04:47 PM

http://www.businesswire.com/news/home/20180925006183/en

AP RADIO
Update hourly